- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
How Long Should Patients Fast after Endoscopic Hemostasis for Non-Variceal Upper Gastrointestinal Bleeding? Findings from a National Administrative Database
-
- Murata Atsuhiko
- Department of Preventive Medicine and Community Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
-
- Matsuda Shinya
- Department of Preventive Medicine and Community Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Search this article
Description
Background: The appropriate duration of fasting therapy after endoscopic hemostasis for the prevention of recurrent bleeding from non-variceal upper gastrointestinal bleeding (NVUGIB) remains unclear. <br>Objective: To determine the appropriate duration of fasting therapy using a national administrative database. <br>Design: Retrospective cohort study. Setting: 475 hospitals between April and December in 2008. <br>Patients and interventions: 3254 patients with endoscopic hemostasis for NVUGIB. <br>Main outcome measurements: Patients were divided into 5 groups according to duration of fasting therapy, namely 1, 2, 3, 4, and 5 d or more. We compared the risk-adjusted rate of recurrent bleeding in relation to the duration of fasting therapy. Odds ratio (OR) and their 95% confidence intervals (CI) for recurrent bleeding after fasting therapy were estimated using a multiple logistic regression model. <br>Results: Recurrent bleeding rate after fasting therapy significantly differed by fasting duration, at 21.7% of patients with 1 d of fasting therapy, 12.3% with 2 d, 4.8% with 3 d, 4.6% with 4 d, and 3.0% with 5 d or more (p<0.001). Multiple logistic regression analysis showed no significant difference in the risk of recurrent bleeding between fasting for 3 or 4 d and 5 d or more (OR of fasting for 3 d 1.635, 95% CI 0.793–3.366, p=0.182; and OR of fasting for 4 d 1.548, 95% CI 0.705–3.402, p=0.276). <br>Limitations: Use of claims data lacking clinical detail. <br>Conclusions: 3 d of fasting therapy seems to be suitable for the prevention of recurrent bleeding from NVUGIB. <br>
Journal
-
- Asian Pacific Journal of Disease Management
-
Asian Pacific Journal of Disease Management 5 (1), 5-11, 2011
Asian Pacific Society of Health Support Science
- Tweet
Details 詳細情報について
-
- CRID
- 1390282680264880384
-
- NII Article ID
- 130004504455
-
- ISSN
- 18823130
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed
